A Mandl, S Jasmine, Teg Krueger, R Kumar, I M Coleman, S L Dalrymple, L Antony, D M Rosen, Y Jing, B Hanratty, R A Patel, L Jin-Yih, J Dias, C A Celatka, A E Tapper, M Kleppe, M Kanayama, V Speranzini, Y Z Wang, J Luo, E Corey, L A Sena, R A Casero, T Lotan, B J Trock, S K Kachhap, S R Denmeade, M A Carducci, A Mattevi, M C Haffner, P S Nelson, H Y Rienhoff, J T Isaacs, W N Brennen
UNLABELLED: Lysine-specific demethylase 1 (LSD1 or KDM1A ) has emerged as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Among mCRPC subtypes, neuroendocrine prostate cancer (NEPC) is an exceptionally aggressive variant driven by lineage plasticity, an adaptive resistance mechanism to androgen receptor axis-targeted therapies. Our study shows that LSD1 expression is elevated in NEPC and associated with unfavorable clinical outcomes...
January 22, 2024: bioRxiv